TY - JOUR T1 - Identification and Analysis of Novel Synovial Tissue-based Biomarkers and Interacting Pathways for Rheumatoid Arthritis JF - medRxiv DO - 10.1101/2021.03.19.21253995 SP - 2021.03.19.21253995 AU - Paridhi Latawa Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.19.21253995.abstract N2 - Rheumatoid arthritis (RA) is an inflammatory disorder with autoimmune pathogenesis characterized by the immune system attacking the synovium. It is a clinically heterogeneous disease that affects approximately 1.2 million Americans and 20 million people worldwide. It is advantageous to diagnose RA before extensive erosion as treatments are more effective at early stages. RA treatments have made notable progress, yet a significant number of patients still fail to respond to current medication and most of these come with harmful side effects. While the mechanistic reason for such failure rates remains unknown, the cellular and molecular signatures in the synovial tissues of patients with RA are likely to play a role in the variable treatment response and heterogeneous clinical evolution. While blood-based criteria are currently employed for diagnostics and treatments. such serologic parameters do not necessarily reflect biological actions in the target tissue of the patient and are relatively nonspecific to RA. Synovial tissue-based biomarkers are especially attractive as they can provide a confirmed diagnosis for RA. The shortage of accurate synovial tissue-based identifiers for RA diagnosis encouraged this research. This study analyzed data from several gene expression studies for differentially expressed genes in donor synovial tissue. Bioinformatics tools were used to construct and analyse protein interaction networks. Analysis deduced that regulating hematopoietic stem cell migration could serve as a potential RA diagnostic. VAV1, CD3G, LCK, PTPN6, ITGB2, CXCL13, CD4, and IL7R are found to be previously unclassified, potential biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approvals were necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary information is available for this paper. All sources are cited, and the repository of differentially expressed genes is provided. Correspondence and requests for materials should be addressed to paridhi.latawa@gmail.com. https://docs.google.com/spreadsheets/d/11yDBMAnymuDmIV6B3Tc2y1ltM_YRYu_QE04G4mHFQHQ/edit#gid=0 ER -